关于使用部分暂时闲置募集资金进行现金管理 到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、使用部分募集资金进行现金管理的情况 润本生物技术股份有限公司(以下简称"公司")于2023年11月9日召开2023年第 三次临时股东大会，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用不超过人民币8.5亿元的闲置募集资金进行现金管理，在上述 额度内，资金可循环滚动使用。具体内容详见公司于2023年10月25日于上海证券交 易所网站(www.sse.com.cn)披露的《关于使用部分暂时闲置募集资金进行现金管理的 公告》(公告编号：2023-002)。 二、 公司本次使用募集资金进行现金管理的情况 证券代码：603193 证券简称：润本股份 公告编号：2024-046 润本生物技术股份有限公司 | 24 | 工行 广州 | | | | | | | 2024- | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 百灵 | ...

广东广信君达律师事务所 关于润本生物技术股份有限公司 2024 年第三次临时股东大会的法律意见书 致：润本生物技术股份有限公司 广东广信君达律师事务所（以下简称"本所"）接受润本生物技术股份有限公司（以下简 称"公司"）的委托，指派张伟、马小希律师（以下简称"本律师"）出席了公司于 2024 年 11 月 11 日（星期一）下午 14:00 在广东省广州市天河区华夏路 28 号富力盈信大厦 40 楼公司 会议室召开的 2024 年第三次临时股东大会（以下简称"本次股东大会"），并依据《中华人 民共和国公司法》、《中华人民共和国证券法》、《上市公司股东大会规则》、《上海证券交 易所股票上市规则》等中国现行法律、法规和其它规范性法律文件（以下合称"法律法规"） 以及《润本生物技术股份有限公司章程》（以下简称"公司章程"）的有关规定，就本次股东 大会的召集和召开程序、出席会议人员的资格和召集人资格、表决程序和表决结果等相关事宜 出具法律意见。 为出具本法律意见书，本律师听取了公司就有关事实的陈述和说明，审查了公司提供的相 关文件，包括但不限于： 1. 公司章程； 2. 第二届董事会第六次会议决议公告； 3. 公司于 ...

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2024 年 11 月 11 日 (二)股东大会召开的地点：广东省广州市天河区华夏路 28 号富力盈信大厦 40 楼 润本生物技术股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 162 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 334,684,032 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 82.7210 | 证券代码：603193 证券简称：润本股份 公告编号：2024-045 润本生物技术股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2、 议案名称：关于续聘会计师事务所的议案 审议结果：通过 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集 ...

二、《募集资金专户存储三方监管协议》、《募集资金专户存储四方监管 协议》的签订情况和募集资金专户的开立情况 为了更便于募集资金的存放与使用，维护投资者的合法权益，确保公司募 投项目顺利开展，提高募集资金使用效率，根据《上市公司监管指引第 2 号— —上市公司募集资金管理和使用的监管要求》，公司于 2024 年 8 月 15 日召开 第二届董事会第四次会议，审议通过了《关于增设募集资金专用账户的议案》， 同意公司新增设立募集资金专项账户，用于首次公开发行股票募集资金的存储 和使用，并授权董事长或其指定人员全权办理与募集资金专用账户有关的事宜， 包括但不限于募集资金专用账户开立、募集资金监管协议签署等相关事项。 证券代码：603193 证券简称：润本股份 公告编号：2024-047 润本生物技术股份有限公司 关于签订募集资金专户存储监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意润本生物技术股份有限公司 首次公开发行股票注册的批复》（证监许可[2023] ...

润本生物技术股份有限公司 2024 年第三次临时股东大会会议资料 润本生物技术股份有限公司 2024 年第三次临时股东大会 会议资料 2024 年 11 月 5 日 1 润本生物技术股份有限公司 2024 年第三次临时股东大会会议资料 目 录 | 2024 年第三次临时股东大会须知…………………………………………………3 | | | --- | --- | | 2024 年第三次临时股东大会议程…………………………………………………5 | | | 议案一：修改经营范围、修订《公司章程》 并办理工商变更登记的议案 | …...7 | | 议案二：关于续聘会计师事务所的议案……………………….… 9 | | | 议案三：关于使用部分超募资金永久补充流动资金的议案…………………….10 | | 2 润本生物技术股份有限公司 2024 年第三次临时股东大会会议资料 股东大会会议须知 三、请参会人员自觉遵守会场秩序，进入会场后将手机关闭或调至震动状态； 除出席会议的股东（或股东代表）、公司董事、监事、高级管理人员、见证律师、 相关工作人员以及董事会邀请的人员外，公司有权拒绝其他人员进入会场。 四、股东在议案讨论阶段可就 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected return exceeding 15% compared to the CSI 300 index [6][9]. Core Insights - The company has shown strong financial performance with a revenue increase of 25.98% year-on-year, reaching 1.038 billion yuan in the first three quarters of 2024, and a net profit growth of 44.35%, amounting to 261 million yuan [3][4]. - The introduction of new products, particularly in the infant care segment, is expected to drive further growth, especially during the peak season [5]. - The company maintains a robust profit margin, with a gross margin of 57.57% and a net margin of 27.55% in Q3 2024, reflecting improved profitability [4][5]. Financial Performance Summary - **Revenue Forecast**: The company is projected to achieve revenues of 1.341 billion yuan in 2024, 1.705 billion yuan in 2025, and 2.133 billion yuan in 2026 [3][7]. - **Net Profit Forecast**: Expected net profits are 297 million yuan for 2024, 366 million yuan for 2025, and 454 million yuan for 2026 [3][7]. - **Earnings Per Share (EPS)**: EPS is forecasted to be 0.73 yuan in 2024, 0.91 yuan in 2025, and 1.12 yuan in 2026 [3][7]. - **Valuation Metrics**: The company’s price-to-earnings (P/E) ratio is projected to decrease from 33.40 in 2024 to 21.86 in 2026, indicating potential for value appreciation [3][7]. Market Position and Strategy - The company is focusing on niche markets such as infant care and mosquito repellent products, leveraging a strategy of "big brand, small categories" to meet diverse consumer needs [5]. - The report highlights the company's increasing market recognition and the trend of domestic product substitution, which is expected to enhance its performance [5].

Investment Rating - The report maintains a "Buy" rating for Runben Co Ltd (603193) [3][4] Core Views - Runben Co Ltd achieved rapid growth in Q3 net profit attributable to parent company, with significant year-on-year improvement in profitability [1] - The company's focus on mosquito repellent and personal care products, coupled with its supply chain advantages and efficient operations, positions it well for continued growth [3] - Future performance is expected to maintain rapid growth driven by R&D and new product launches [3] Financial Performance Q3 2024 Results - Revenue reached RMB 10.38 billion in Q1-Q3 2024, up 25.98% YoY [1] - Net profit attributable to parent company was RMB 2.61 billion in Q1-Q3 2024, up 44.35% YoY [1] - Q3 revenue increased 20.10% YoY, with net profit up 31.98% YoY [1] Profitability - Gross margin increased 2.21 percentage points to 58.33% in Q1-Q3 2024 [2] - Net margin rose 3.20 percentage points to 25.15% in Q1-Q3 2024 [2] - Sales expense ratio increased 1.93 percentage points to 27.27% in Q1-Q3 2024 [2] Product Performance - Mosquito repellent products revenue reached RMB 0.89 billion in Q3 2024, up 16.15% YoY [2] - Baby care products revenue was RMB 1.50 billion in Q3 2024, up 26.72% YoY [2] - Essential oil series revenue reached RMB 0.46 billion in Q3 2024, up 15.35% YoY [2] Financial Forecasts Income Statement - Revenue is projected to grow from RMB 12.31 billion in 2024E to RMB 17.18 billion in 2026E [5][7] - Net profit attributable to parent company is expected to increase from RMB 2.97 billion in 2024E to RMB 4.52 billion in 2026E [5][7] Valuation Metrics - EPS is forecasted to grow from RMB 0.73 in 2024E to RMB 1.12 in 2026E [5][7] - PE ratio is expected to decrease from 33.45x in 2024E to 21.95x in 2026E [5][7] Balance Sheet - Total assets are projected to increase from RMB 22.34 billion in 2024E to RMB 28.20 billion in 2026E [7] - Shareholders' equity attributable to parent company is expected to grow from RMB 21.19 billion in 2024E to RMB 26.66 billion in 2026E [7]

Investment Rating - The report assigns an "Outperform" rating to Runben Co Ltd (603193) [1] Core Views - Runben has established a strong brand presence in the mosquito repellent category and is rapidly expanding into the high-margin baby care segment [5] - The company has built an online-driven omnichannel sales network, with online sales accounting for 72% of total revenue in 1H24 [5] - Runben has achieved steady growth in operating performance, with 1-3Q24 revenue and net profit increasing by 26% and 44% YoY respectively [5] - The company's gross margin reached 58 3% in 1-3Q24, up 2 2 percentage points YoY [5] Industry Analysis - The mosquito repellent and baby care industries are highly fragmented, with the top 5 baby care brands accounting for only 14% market share in China [5] - The baby care market is becoming more segmented, with products tailored to different body parts, functions, and scenarios [5] - Scientific parenting concepts are driving demand for more specialized baby care products [5] Competitive Advantages - Runben offers safe and gentle products, with mosquito repellents that are more environmentally friendly than traditional options [6] - The company has strong R&D capabilities, with 11 national invention patents and 11 utility model patents as of 1H24 [6] - Runben's integrated R&D, production, and sales model allows for better cost control and quality assurance [6] - The company achieved a net profit margin of 25 2% in 1-3Q24 [6] Growth Drivers - Frequent new product launches and price increases are driving growth, with 50+ new products introduced in 1H24 [6] - Runben is expanding its offline distribution channels, with non-platform distributors covering over 30 provinces and regions [8] - The company has a strong online presence, ranking first in maternal and infant care products on major e-commerce platforms during the 2024 618 shopping festival [8] Financial Projections - Revenue is expected to grow at a CAGR of 26 8% from 2024 to 2026, reaching 21 09 billion yuan by 2026 [9] - Net profit is projected to increase at a CAGR of 31 9% over the same period, reaching 5 19 billion yuan by 2026 [9] - The gross margin is forecast to improve from 58 8% in 2024 to 60 8% in 2026 [9] Business Segment Analysis - Mosquito repellent products: Expected to grow at a CAGR of 25 5% from 2024 to 2026, reaching 6 42 billion yuan by 2026 [10] - Baby care products: Projected to grow at a CAGR of 33 3% from 2024 to 2026, reaching 12 36 billion yuan by 2026 [10] - Essential oil products and others: Forecast to grow at a CAGR of 7 3% from 2024 to 2026, reaching 2 3 billion yuan by 2026 [10] Valuation - The report values Runben at 25-30x 2025E PE, implying a market cap range of 103 43-124 12 billion yuan [9] - The target price range is 25 57-30 68 yuan per share [9]

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company's performance in Q1-Q3 2024 met expectations, with revenue increasing by 26% to 1.04 billion yuan and net profit attributable to shareholders rising by 44% to 261 million yuan [1] - The third quarter saw a seasonal boost in sales for baby care products, with revenue up by 20% and net profit up by 32% [1] - The company is expected to maintain steady growth through capacity expansion, product line diversification, and channel expansion, with projected revenues of 1.34 billion yuan in 2024, 1.70 billion yuan in 2025, and 2.06 billion yuan in 2026, reflecting growth rates of 30%, 26%, and 22% respectively [3] Financial Summary - For Q1-Q3 2024, the gross margin was 58.3% (up 2 percentage points), and the net margin was 25.2% (up 3.2 percentage points) [1] - In Q3 2024, the revenue breakdown by product line showed mosquito repellent at 31%, baby care at 53%, and essential oils at 16% [1] - The average selling price for mosquito repellent was 5.5 yuan (up 2%), baby care products at 7.9 yuan (up 2%), and essential oils at 9.1 yuan (up 14%) [1] Sales Performance - Sales through Douyin (TikTok) increased significantly, with a 56% year-on-year growth from January to September 2024, and a 60% increase in September alone [2] - The company launched new products, including the egg yolk oil special care cream, which performed well in sales [2] Earnings Forecast - The forecast for net profit attributable to shareholders is 322 million yuan in 2024, 406 million yuan in 2025, and 490 million yuan in 2026, with growth rates of 42%, 26%, and 21% respectively [3]

Investment Rating - The report maintains a "Buy" rating for the company, with an updated target price of 30.69 yuan, reflecting an increase of 9.37 yuan from the previous estimate [4][5]. Core Views - The company's performance in Q3 2024 met expectations, with steady growth across various product categories during the off-season. The recent launch of autumn and winter baby products on Douyin, including egg yolk oil essence cream, has shown promising results, leading to an optimistic outlook for Q4 during the peak season for baby products [2][4]. Financial Summary - For the first three quarters of 2024, the company reported revenues of 1.038 billion yuan, a year-on-year increase of 26%, with net profit attributable to the parent company reaching 261 million yuan, up 44% year-on-year. In Q3 alone, revenues were 293 million yuan, a 20% increase year-on-year, while net profit was 81 million yuan, reflecting a 32% increase [4][5]. - The gross profit margin for Q3 2024 was 57.6%, an increase of 0.11 percentage points year-on-year. The net profit margin for Q3 was 27.55%, up 2.48 percentage points year-on-year [4][5]. - The company expects revenues to grow to 1.322 billion yuan in 2024, 1.661 billion yuan in 2025, and 2.034 billion yuan in 2026, with corresponding net profits projected at 319 million yuan, 402 million yuan, and 493 million yuan respectively [5][11]. Product and Channel Performance - In Q3 2024, the company experienced robust growth in various product categories, with baby care products, mosquito repellent, and essential oils seeing revenue increases of 28%, 18%, and 17% year-on-year respectively. Douyin's sales grew over 30% year-on-year, while Tmall remained stable [4][5]. - The company has successfully launched new products, which have significantly boosted sales on Douyin, with notable growth in GMV since late September [4][5]. Long-term Outlook - The company is expected to benefit from a reshaping of competition in the baby care product category, focusing on product channel expansion and maintaining high growth rates. The company positions its products competitively in the 0-50 yuan price range, leveraging a self-built supply chain for cost advantages [4][5].